CN110652484A - Shampoo formula for daily maintenance of psoriasis skin - Google Patents
Shampoo formula for daily maintenance of psoriasis skin Download PDFInfo
- Publication number
- CN110652484A CN110652484A CN201911065219.9A CN201911065219A CN110652484A CN 110652484 A CN110652484 A CN 110652484A CN 201911065219 A CN201911065219 A CN 201911065219A CN 110652484 A CN110652484 A CN 110652484A
- Authority
- CN
- China
- Prior art keywords
- parts
- sodium
- skin
- psoriasis
- shampoo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 66
- 239000002453 shampoo Substances 0.000 title claims abstract description 60
- 238000012423 maintenance Methods 0.000 title claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 41
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 40
- 239000002994 raw material Substances 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 239000004359 castor oil Substances 0.000 claims abstract description 20
- 235000019438 castor oil Nutrition 0.000 claims abstract description 20
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims abstract description 20
- 229940079868 disodium laureth sulfosuccinate Drugs 0.000 claims abstract description 20
- YGAXLGGEEQLLKV-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-2-sulfonatobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)CC(C([O-])=O)S([O-])(=O)=O YGAXLGGEEQLLKV-UHFFFAOYSA-L 0.000 claims abstract description 20
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 20
- 239000011780 sodium chloride Substances 0.000 claims abstract description 20
- 229940057950 sodium laureth sulfate Drugs 0.000 claims abstract description 20
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 claims abstract description 20
- GOJYXPWOUJYXJC-UHFFFAOYSA-M sodium;2-[1-(2-hydroxyethyl)-2-undecyl-4,5-dihydroimidazol-1-ium-1-yl]acetate;hydroxide Chemical compound [OH-].[Na+].CCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O GOJYXPWOUJYXJC-UHFFFAOYSA-M 0.000 claims abstract description 20
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims abstract description 20
- 239000012528 membrane Substances 0.000 claims abstract description 9
- 150000003863 ammonium salts Chemical group 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims abstract 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 45
- 239000000284 extract Substances 0.000 claims description 37
- 238000003756 stirring Methods 0.000 claims description 31
- 238000002156 mixing Methods 0.000 claims description 30
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 24
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 22
- 239000008213 purified water Substances 0.000 claims description 22
- 229960004889 salicylic acid Drugs 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 claims description 19
- QHCKTAVCXCIDCU-UHFFFAOYSA-M 4-hydroxybutyl-bis(2-hydroxyethyl)-methylazanium chloride Chemical compound [Cl-].OCCCC[N+](C)(CCO)CCO QHCKTAVCXCIDCU-UHFFFAOYSA-M 0.000 claims description 19
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 claims description 19
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 claims description 19
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 claims description 19
- 240000001548 Camellia japonica Species 0.000 claims description 16
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 16
- 235000018597 common camellia Nutrition 0.000 claims description 16
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 16
- 238000005303 weighing Methods 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 claims description 12
- 229940119485 safflower extract Drugs 0.000 claims description 12
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 claims description 12
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 claims description 12
- 240000001745 Rheum palmatum Species 0.000 claims description 11
- 235000008090 Rheum palmatum Nutrition 0.000 claims description 11
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000001185 psoriatic effect Effects 0.000 claims description 10
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 claims description 9
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 claims description 9
- 229940084038 salix alba bark extract Drugs 0.000 claims description 9
- 229960001484 edetic acid Drugs 0.000 claims description 8
- 229960002668 sodium chloride Drugs 0.000 claims description 7
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 6
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 239000010282 Emodin Substances 0.000 claims description 6
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 6
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 6
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 6
- 235000019485 Safflower oil Nutrition 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000005487 catechin Nutrition 0.000 claims description 6
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 claims description 6
- 229950001002 cianidanol Drugs 0.000 claims description 6
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 6
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 6
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000003813 safflower oil Substances 0.000 claims description 6
- 235000005713 safflower oil Nutrition 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 5
- 239000001263 FEMA 3042 Substances 0.000 claims description 5
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 229940095673 shampoo product Drugs 0.000 claims description 5
- 235000015523 tannic acid Nutrition 0.000 claims description 5
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 5
- 229940033123 tannic acid Drugs 0.000 claims description 5
- 229920002258 tannic acid Polymers 0.000 claims description 5
- 241000219061 Rheum Species 0.000 claims description 4
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229940023569 palmate Drugs 0.000 claims description 3
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 210000004761 scalp Anatomy 0.000 abstract description 33
- 208000003251 Pruritus Diseases 0.000 abstract description 25
- 238000011282 treatment Methods 0.000 abstract description 20
- 206010040882 skin lesion Diseases 0.000 abstract description 10
- 231100000444 skin lesion Toxicity 0.000 abstract description 10
- 230000007774 longterm Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000010276 construction Methods 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 62
- 230000000694 effects Effects 0.000 description 21
- 208000001840 Dandruff Diseases 0.000 description 20
- 239000003814 drug Substances 0.000 description 14
- 230000037380 skin damage Effects 0.000 description 14
- 230000003902 lesion Effects 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 230000007803 itching Effects 0.000 description 11
- 230000003078 antioxidant effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 229920000832 Cutin Polymers 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000005713 exacerbation Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000006748 scratching Methods 0.000 description 7
- 230000002393 scratching effect Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 231100000245 skin permeability Toxicity 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 229940120668 salicin Drugs 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010064503 Excessive skin Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 2
- 241000899950 Salix glauca Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000002081 peroxide group Chemical group 0.000 description 2
- 229940081510 piroctone olamine Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 241000608174 Gymnadenia Species 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000575041 Homo sapiens Male-enhanced antigen 1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 102100025532 Male-enhanced antigen 1 Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000023368 generalized pustular psoriasis Diseases 0.000 description 1
- 208000021245 head disease Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940124508 injectable medicine Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229940119569 wormwood extract Drugs 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a shampoo formula for daily maintenance of psoriasis skin, which comprises the following raw materials in parts by weight: the skin care cream comprises, by weight, 30-40 parts of a main material composition, 3-5 parts of sodium laureth sulfate, 3-5 parts of sodium lauroamphoacetate, 3-5 parts of sodium chloride, 3-5 parts of sodium methyl cocoyl taurate, 3-5 parts of disodium laureth sulfosuccinate, 1-3 parts of cocamide MEA (membrane electrode assembly), 221-3 parts of polyquaternary ammonium salt, 1-3 parts of PEG-40 hydrogenated castor oil and 1-3 parts of cocamidopropyl betaine. The shampoo formula for daily maintenance of the psoriasis skin forms a special daily maintenance use formula for the psoriasis through formulation construction of a large number of experiments, is suitable for the shampoo for daily scalp skin, enables the prevention and treatment concept of controlling the psoriasis to enter daily necessities of patients in a subtler way, and is easier to control pruritus and discomfort of scalp skin lesion areas of psoriasis crowds in a long-term and stable manner and continuously improve the scalp skin with psoriasis tendency.
Description
Technical Field
The invention relates to the technical field of skin care, in particular to a shampoo formula for daily maintenance of psoriasis skin.
Background
Psoriasis is commonly called psoriasis, is a common chronic recurrent inflammatory skin disease, and is characterized in that red papules or plaques are covered with multiple layers of silvery-white scales which are better developed on the extending sides of limbs, the scalp and the back, and severe skin damage can cause the whole body to be generalized and can cause high fever, pustules, red skin disease-like changes and large and small arthrosis of the whole body. Pathologically, there are telangiectasia, tissue edema, inflammatory cell infiltration and inflammatory reaction of insufficiency of keratin, and hyperproliferation of epidermal cell keratin. According to the characteristics of skin lesions, skin lesions usually occur on scalp, around limbs and joints, trunk and back, face, auricle or ear canal, around nasal cavity, perineum, anus, scrotum and prepuce, and nails, and are often accompanied by itching, red-hot skin, and accumulation of a large amount of silvery-white scales. The above skin manifestations, especially of scalp lesions, are significant and seriously afflict the individual life, work and increase the psychological burden of the psoriasis sufferers. Psoriasis is a polygenic hereditary disease, involves a plurality of inducing factors such as infection, trauma and mental stress on the basis of genetic predisposition, and is related to metabolic disorders and immune dysfunction.
The aim of current psoriasis treatment is to prevent the acute attack of psoriasis and to prolong its remission as much as possible. The mild patients are mainly treated by external medicines, and the severe patients or patients with acute attack difficult to control can be treated by whole body. Adverse reactions were closely observed when selecting treatments. After the control of the disease, the patient needs to adhere to consolidation treatment to avoid rebound caused by sudden withdrawal of the medicine. The commonly used topical drugs are glucocorticoid preparations, keratolytic agents, calcipotriol, etc., which are often combined with ultraviolet irradiation to enhance the drug effect. Clinically, psoriasis vulgaris with poor control can be further worsened and developed into erythrodermic psoriasis, generalized pustular psoriasis and arthropathic psoriasis, and the effect is difficult to be achieved by adopting the external medicine alone, so that the general treatment is required. The oral and injectable medicines can be selected from glucocorticoid, chemotherapeutic drugs, immunosuppressant, retinoic acid, biological agent, etc.
The areas of the scalp rash and the skin lesions of the psoriasis are generally accompanied with pruritus of different degrees, because the rash of the psoriasis has inflammation, and simultaneously, because the keratosis of the horny layer cells of the scalp skin lesions is incomplete, loose in arrangement and damaged in normal barrier function, the skin is dry due to excessive skin moisture loss, so that the scalp skin of a patient has pruritus feeling; and dry scalp skin is sensitive to external irritation. Patients in the advanced stage of the disease have severe itching due to skin damage and obvious inflammation or stimulation of external factors such as medicines, or due to high sensitivity of skin feeling of the patients. If not properly treated, scratching of the lesion area may lead to an exacerbation of symptoms in the lesion area or to a recurrence of the lesion area in a quiescent state, resulting in a vicious circle. Therefore, patients in the resting stage should have a better understanding of an effective common scalp care routine and use a special daily psoriasis skin care lotion to control itching, reduce scratching, control the lesions in the resting stage and reduce their recurrence and exacerbations.
Although psoriasis is a chronic skin disease easy to relapse, no radical treatment method is available at present, but the psoriasis can be kept in a stationary period for a long time through correct and appropriate treatment and daily maintenance without influencing normal work and life.
Today, people in the world cannot treat psoriasis completely and completely. The advertisement of 'Yipingling' and 'instant effect for treating psoriasis' is invented, the short-term curative effect of the rash is only considered, the toxic and side effect accumulated by long-distance medicines is not considered, a large amount of cortical hormone or anticancer medicine is used randomly, although the effect is achieved in a short term, serious rebound is generated after a few days, the disease condition is obviously worse than before, the treatment is more difficult to treat, the organ and the immunity of a collective are damaged, and serious even difficult-to-recover adverse reactions are generated, such as liver and kidney damage, and various infections and tumors are induced.
The new medical modalities for the treatment of psoriasis are: not only treatment, but also patient self-care; not only the psychological treatment of patients is important, but also a good social environment is formed to prevent and treat psoriasis. Providing self-care knowledge requires patients to adopt a disease-preventive posture to face psoriasis without relying on drugs at a glance, since even if the drugs are used correctly, the patients' lifestyle can seriously affect the efficacy of the drugs.
Psoriasis patients often need long-term, lifelong, daily use during treatment and long-term external use often causes new skin problems; meanwhile, the skin of the patient with psoriasis has the skin with excessive increase of skin keratinocytes, neutrophil infiltration and abnormal proliferation and expansion of dermal blood vessels, which can further deteriorate the skin environment of the patient. For an increasingly deteriorating skin environment, there is a need for specialized care products directed specifically to psoriatic skin to improve such psoriatic-prone skin and mitigate the negative effects of various therapeutic agents on the skin. At present, no special washing and protecting product specially aiming at Chinese psoriasis patients exists in China. Psoriasis patients often have a wider scalp skin damage area, and daily necessities (shampoo, soap and the like) on the market are not suitable for the skin damage area of the patients during daily cleaning and maintenance; the skin of the affected area with the medicine is also extremely fragile, and the affected area can relapse and get worse with a little carelessness in daily maintenance. These all increase the psychological stress and mental stress of the patient, affect the clinical therapeutic effect, lead to recurrent attacks of the disease, prolong the duration of the disease, and may induce exacerbations leading to more severe generalized outbreaks.
The shampoo is specially designed for the basic condition of the skin of psoriasis, most of the shampoo in the current market has the effects of removing dandruff and relieving itching, and no daily maintenance shampoo specially used for patients with psoriasis is available. The skin characteristics of psoriasis patients are different from those of the conventional people, the skin keratinocytes of the psoriasis patients excessively grow, the neutrophil infiltration and the dermal blood vessels abnormally proliferate and expand, and the skin environment is abnormally fragile. Meanwhile, due to the skin damage, namely keratosis insufficiency of stratum corneum cells, loose arrangement, damage of normal barrier function and excessive skin moisture loss, the skin is dry, so that the skin of a patient has itching feeling; and dry skin is sensitive to external irritation. Patients in the advanced stage of the disease have severe itching due to skin damage and obvious inflammation or stimulation of external factors such as medicines, or due to high sensitivity of skin feeling of the patients. If not properly treated, scratching the lesion area may lead to an exacerbation of symptoms in the lesion area or to a recurrence of the lesion area during periods of inactivity, resulting in a vicious circle, so that patients in periods of inactivity should better master a set of effective daily skin care routines and use specialized daily psoriatic skin care products to control pruritus, reduce scratching, control the lesion area during periods of inactivity, and reduce recurrence and exacerbation of symptoms.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a shampoo formula for daily maintenance of psoriasis skin, which solves the problems that patients with psoriasis often have wider scalp skin damage areas, the existing shampoo or soap is not suitable for the skin damage areas of the patients during daily cleaning and maintenance, the skin of the skin damage areas using medicines is also extremely fragile, and the psoriasis skin can relapse and aggravate again due to careless daily maintenance. The shampoo is helpful for daily washing and protecting scalp to effectively control pruritus and discomfort in a scalp lesion area, reduce scratching, control the scalp lesion area in a static fading period and reduce relapse and symptom aggravation.
(II) technical scheme
In order to achieve the purpose, the invention is realized by the following technical scheme: a shampoo formula for daily maintenance of psoriasis skin comprises the following raw materials in parts by weight: 30-40 parts of a main material composition, 3-5 parts of sodium laureth sulfate, 3-5 parts of sodium lauroamphoacetate, 3-5 parts of sodium chloride, 3-5 parts of sodium methyl cocoyl taurate, 3-5 parts of disodium laureth sulfosuccinate, 1-3 parts of cocamide MEA, 221-3 parts of polyquaternary ammonium salt, 1-3 parts of PEG-40 hydrogenated castor oil, 1-3 parts of cocamidopropyl betaine, 1-3 parts of hydroxypropyl bis-hydroxyethyl dimethylammonium chloride, 1-3 parts of disodium EDTA, 1-3 parts of methyl chloroisothiazolinone, 1-3 parts of methyl isothiazolinone and the balance of purified water, wherein the main material composition is prepared from 3% of salicylic acid, 0.5% of piroctone ethanolamine salt, 1% of sodium, 0.5% of zinc PCA, 1% of white willow bark extract PCA, 1% of sodium PCA, and the balance of purified water respectively, 0.5 percent of camellia extract, 0.5 percent of safflower extract and 0.5 percent of rhubarb palmate extract.
Preferably, the raw materials comprise the following components: the main material composition comprises 35 parts of sodium laureth sulfate, 4 parts of sodium lauroamphoacetate, 4 parts of sodium chloride, 4 parts of sodium methyl cocoyl taurate, 4 parts of disodium laureth sulfosuccinate, 2 parts of cocamide MEA (membrane electrode assembly), 222 parts of polyquaternary ammonium salt, 2 parts of PEG-40 hydrogenated castor oil, 2 parts of cocamidopropyl betaine, 2 parts of hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, 2 parts of disodium EDTA (ethylene diamine tetraacetic acid), 2 parts of methylchloroisothiazolinone, 2 parts of methylisothiazolinone and the balance of purified water.
Preferably, the raw materials comprise the following components: the main material composition comprises 30 parts of sodium laureth sulfate, 3 parts of sodium lauroamphoacetate, 3 parts of sodium chloride, 3 parts of sodium methyl cocoyl taurate, 3 parts of disodium laureth sulfosuccinate, 1 part of cocamide MEA (membrane electrode assembly), 221 parts of polyquaternary ammonium salt-221, 1 part of PEG-40 hydrogenated castor oil, 1 part of cocamidopropyl betaine, 1 part of hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, 1 part of disodium EDTA (ethylene diamine tetraacetic acid), 1 part of methylchloroisothiazolinone, 1 part of methylisothiazolinone and the balance of purified water.
Preferably, the raw materials comprise the following components: the main material composition comprises 40 parts of sodium laureth sulfate, 5 parts of sodium lauroamphoacetate, 5 parts of sodium chloride, 5 parts of sodium methyl cocoyl taurate, 5 parts of disodium laureth sulfosuccinate, 3 parts of cocamide MEA (membrane electrode assembly), 223 parts of polyquaternary ammonium salt, 3 parts of PEG-40 hydrogenated castor oil, 3 parts of cocamidopropyl betaine, 3 parts of hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, 3 parts of disodium EDTA (ethylene diamine tetraacetic acid), 3 parts of methylchloroisothiazolinone, 3 parts of methylisothiazolinone and the balance of purified water.
Preferably, the camellia extract contains catechin, vitamin C, tannic acid and amino acid components, has excellent moisturizing effect and contains soothing and antioxidant activities.
Preferably, the safflower extract contains carthamin, safflower yellow and safflower oil components, and has obvious effects of resisting oxidation, scavenging free radicals, desensitizing and resisting inflammation.
Preferably, the rheum palmatum extract contains emodin and chrysophanol components, and can promote blood circulation of skin, improve skin permeability, promote absorption of effective components, inhibit bacteria and astringe skin.
Preferably, the preparation method of the shampoo specifically comprises the following steps:
s1, selecting and weighing raw materials: firstly, respectively weighing a main material composition, sodium laureth sulfate, sodium lauroamphoacetate, sodium chloride, sodium methyl cocoyl taurate, disodium laureth sulfosuccinate, cocamide MEA (membrane electrode assembly), polyquaternary ammonium salt-22, PEG-40 hydrogenated castor oil, cocamidopropyl betaine, hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, disodium EDTA (ethylene diamine tetraacetic acid), methylchloroisothiazolinone, methylisothiazolinone and purified water in required parts by weight by using weighing equipment for later use;
s2, preparation of auxiliary materials: sequentially adding sodium laureth sulfate, sodium lauroamphoacetate, sodium chloride, sodium methyl cocoyl taurate, disodium laureth sulfosuccinate, cocamide MEA, polyquaternary ammonium salt-22, PEG-40 hydrogenated castor oil, cocamidopropyl betaine, hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, disodium EDTA, methylchloroisothiazolinone, methylisothiazolinone and purified water which are weighed in the step S1 into a mixing and stirring device, then mixing at the rotation speed of 400-;
s3, mixing of raw materials: adding 3% of salicylic acid in the main material composition measured in the step S1 into the auxiliary material prepared in the step S2, continuously stirring until the salicylic acid is completely dissolved, simultaneously cooling the mixing and stirring equipment, respectively adding 0.5% of piroctone olamine salt, 1% of sodium PCA, 0.5% of zinc PCA, 1% of white willow bark extract, 0.5% of camellia extract, 0.5% of safflower extract and 0.5% of rheum palmatum extract when the temperature is reduced to 50 ℃, and stirring at the rotating speed of 600 + 700r/min until the materials are completely dissolved, thereby completing the mixing of the raw materials;
s4, adjusting the pH of the finished product: and (5) adding a pH regulator into the mixed raw materials obtained in the step S3, uniformly stirring and mixing, and regulating the pH value of the raw materials to 6.5 to obtain a finished shampoo product for daily maintenance of the skin with psoriasis.
3% salicylic acid: salicylic acid can dissolve the substance between horny layers, so as to make horny layer fall off, remove horny layer with excessive accumulation, and promote metabolism. The intercellular cement is dissolved to reduce the intercellular adhesion of stratum corneum, and simultaneously, the pH value of the stratum corneum can be reduced to improve the hydration and softening effects, so as to realize the effects of removing scales and softening cutin, salicylic acid is used for treating psoriasis before, but 10% -20% salicylic acid is mostly adopted, the concentration has obvious stimulation effect on the skin, although the skin damage area of the psoriasis has certain cutin softening effect, the skin is easy to cause acid burn and stimulation, the formula adopts 3% salicylic acid to act on the stratum corneum to soften the cutin, the stimulation effect on the skin is also reduced to a safe range, and the formula also has certain regulation effect on the metabolism of the skin.
0.5% piroctone olamine salt: it can radically block the external channel of scalp scale by means of sterilization, antioxidation and decomposition of peroxide so as to effectively radically cure dandruff and stop scalp itching.
1% sodium PCA: is the main component in the stratum corneum of the skin and is one of natural moisturizing factors.
0.5% zinc PCA: the L-zinc pyrrolidone carboxylate (PCA-zinc) is characterized in that sodium ions in PCA active sodium are replaced by zinc ions with an antibacterial effect, and a moisturizing effect and excellent antibacterial performance are provided for skin, scientific research shows that zinc can reduce excessive secretion of sebum through inhibition of 5-a reductase, supplement zinc elements for skin, help to keep normal metabolism of skin, synthesis of DNA, cell division, synthesis of protein and activity of various enzymes in human tissues, and cause skin damage areas of psoriasis patients to be abnormal and fragile due to long-term chronic stimulation, keratinization and vascularization, and the combined use of dipotassium glycyrrhizinate, sodium PCA and zinc PCA can effectively relieve skin inflammatory reaction, promote moisturizing and improve normal metabolism of skin cells, and greatly relieve local inflammation and pruritus caused by dryness caused by psoriasis, and help the surrounding cells to metabolize normally.
1% white willow bark extract (salicin): the white willow bark is fermented by lactobacillus, and then a series of filtering procedures are adopted to concentrate the content of natural salicylic acid, salicin can up-regulate HSP70 protein, exert the mild antibacterial and anti-inflammatory effects, promote cell renewal, and have effective clearing effect on removing excessive keratinized skin formed by psoriasis.
0.5% camellia extract: contains rich catechin, vitamin C, tannin and amino acid components, has excellent moisturizing effect, and has soothing and antioxidant activities.
0.5% safflower extract: contains carthamin, safflower yellow, safflower oil, and Carthami flos extract, and has effects of resisting oxidation, scavenging free radicals, desensitizing, and relieving inflammation.
0.5% rheum palmatum extract: the main extract components contain emodin and chrysophanol, and can promote skin blood circulation, increase skin permeability, promote absorption of effective components, inhibit bacteria, and astringe skin.
(III) advantageous effects
The invention provides a shampoo formula for daily maintenance of psoriatic skin. Compared with the prior art, the method has the following beneficial effects: the shampoo formula for daily maintenance of psoriasis skin is characterized in that active ingredients of 3% salicylic acid, 0.5% piroctone olamine, 1% sodium PCA, 0.5% zinc PCA, 1% white willow bark extract-salicin, 0.5% camellia extract, 0.5% safflower extract and 0.5% rhubarb gymnadenia palmata extract are adopted, the formula is different from common and conventional shampoos on the market, and repeated experiments prove that the 3% salicylic acid is used, the 3% salicylic acid is safe and non-irritant to use and can be used safely for a long time, so that regulation and control of a cutin area of psoriasis skin damage are realized, the salicylic acid can dissolve a constitutional substance between cutins to ensure that the cutin falls off, can remove the accumulated thick cutin layer and promote metabolism of the cutin area, compared with related anti-dandruff products, the anti-dandruff components mostly adopt zinc pyrithione, sulfur, selenium sulfide, coal tar oil and the like, and the anti-dandruff components have certain effect on conventional scalp anti-dandruff, although the anti-dandruff shampoo has a certain anti-dandruff effect on skin lesion areas of psoriasis, the anti-dandruff shampoo is easy to cause skin stimulation, so that patients cannot use the anti-dandruff shampoo for a long time, the scalp environment of the patients with psoriasis is often relatively complex, sebum is excessively secreted, microflora metabolism and individual sensitivity are realized, skin lesions and dandruff are possibly associated with fungal infection caused by malassezia on the scalp, the intercellular lipid level of the scalp stratum corneum is reduced, barrier function is damaged, 0.5% of piroctone olamine, ethanolamine salt also has excellent broad-spectrum bactericidal and bacteriostatic properties, external channels generated by scalp scales can be fundamentally blocked through the bactericidal and antioxidant effects and the decomposition of peroxides, so that dandruff and scalp itch can be effectively controlled, the skin inflammatory reaction can be effectively relieved through the combined use of 1% of sodium PCA and 0.5% of zinc PCA, moisture retention is promoted, and the normal metabolism of skin cells is improved, can greatly relieve local inflammation caused by psoriasis and pruritus caused by dryness, and can help normal metabolism of peripheral cells. The camellia extract 0.5%, the kelp 0.5%, the wormwood extract 0.5% and the rose extract 0.5% have excellent moisturizing effect, and have soothing and antioxidant activities, and have regulating effects on various biomarkers affecting inflammation and immune response. The shampoo is used for shampoo for daily maintenance of the psoriasis, so that the prevention and treatment idea for controlling the psoriasis can enter daily supplies of patients in a stealthy and adelomorphic manner, and the scalp skin lesion area of the psoriasis can be controlled more easily, stably and durably and the scalp skin with the psoriasis tendency can be improved continuously. The shampoo is helpful for daily washing and protecting scalp to effectively control discomfort of scalp lesion areas, reduce scratching, control the scalp lesion areas in a static fading period and reduce relapse and symptom aggravation.
Drawings
Fig. 1 is a flow chart of a preparation method of shampoo of the invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1, the embodiment of the present invention provides three technical solutions: a shampoo formula for daily maintenance of psoriasis skin comprises the following raw materials in parts by weight: 30-40 parts of a main material composition, 3-5 parts of sodium laureth sulfate, 3-5 parts of sodium lauroamphoacetate, 3-5 parts of sodium chloride, 3-5 parts of sodium methyl cocoyl taurate, 3-5 parts of disodium laureth sulfosuccinate, 3-3 parts of cocamide MEA1, 221-3 parts of polyquaternary ammonium salt, 1-3 parts of PEG-40 hydrogenated castor oil, 1-3 parts of cocamidopropyl betaine, 1-3 parts of hydroxypropyl bis-hydroxyethyl dimethylammonium chloride, 1-3 parts of disodium EDTA, 1-3 parts of methyl chloroisothiazolinone, 1-3 parts of methyl isothiazolinone and the balance of purified water, wherein the main material composition is prepared from 3% of salicylic acid, 0.5% of piroctone ethanolamine salt, 1% of sodium PCA, 0.5% of zinc PCA, 1% of white willow bark extract, and the balance of purified water respectively, 0.5 percent of camellia extract, 0.5 percent of safflower extract and 0.5 percent of rhubarb palmate extract.
A preparation method of shampoo for daily maintenance of psoriasis skin specifically comprises the following steps:
example 1
S1, selecting and weighing raw materials: firstly, respectively weighing 35 parts of main material composition, 4 parts of sodium laureth sulfate, 4 parts of sodium lauroamphoacetate, 4 parts of sodium chloride, 4 parts of sodium methyl cocoyl taurate, 4 parts of disodium laureth sulfosuccinate, 2 parts of cocamide MEA, 2 parts of polyquaternium-22, 2 parts of PEG-40 hydrogenated castor oil, 2 parts of cocamidopropyl betaine, 2 parts of hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, 2 parts of EDTA disodium, 2 parts of methylchloroisothiazolinone, 2 parts of methylisothiazolinone and purified water according to the required weight ratio by using weighing equipment for later use;
s2, preparation of auxiliary materials: sequentially adding sodium laureth sulfate, sodium lauroamphoacetate, sodium chloride, sodium methyl cocoyl taurate, disodium laureth sulfosuccinate, cocamide MEA, polyquaternary ammonium salt-22, PEG-40 hydrogenated castor oil, cocamidopropyl betaine, hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, disodium EDTA, methylchloroisothiazolinone, methylisothiazolinone and purified water which are weighed in the step S1 into a mixing and stirring device, then mixing at the rotating speed of 450r/min, gradually heating and stirring to 60 ℃, and stirring for 35min to obtain auxiliary materials;
s3, mixing of raw materials: adding 3% of salicylic acid in the main material composition measured in the step S1 into the auxiliary material prepared in the step S2, continuously stirring until the salicylic acid is completely dissolved, simultaneously cooling the mixing and stirring equipment, respectively adding 0.5% of piroctone olamine salt, 1% of sodium PCA, 0.5% of zinc PCA, 1% of white willow bark extract, 0.5% of camellia extract, 0.5% of safflower extract and 0.5% of rheum palmatum extract when the temperature is reduced to 50 ℃, stirring at the rotating speed of 650r/min until the materials are completely dissolved, thereby completing the mixing of the raw materials, wherein the camellia extract contains catechin, vitamin C, tannic acid and amino acid components, has excellent efficacy, contains soothing and antioxidant activities, contains carthamin extract, carthamin yellow and safflower oil components, and has obvious antioxidant, free radical scavenging and anti-inflammatory effects, the Rheum palmatum extract contains emodin and chrysophanol components, and can promote blood circulation of skin, improve skin permeability, promote absorption of effective components, inhibit bacteria, and astringe skin;
s4, adjusting the pH of the finished product: and (5) adding a pH regulator into the mixed raw materials obtained in the step S3, uniformly stirring and mixing, and regulating the pH value of the raw materials to 6.5 to obtain a finished shampoo product for daily maintenance of the skin with psoriasis.
Example 2
S1, selecting and weighing raw materials: firstly, respectively weighing 30 parts of main material composition, 3 parts of sodium laureth sulfate, 3 parts of sodium lauroamphoacetate, 3 parts of sodium chloride, 3 parts of sodium methyl cocoyl taurate, 3 parts of disodium laureth sulfosuccinate, 1 part of cocamide MEA, 1 part of polyquaternium-22, 1 part of PEG-40 hydrogenated castor oil, 1 part of cocamidopropyl betaine, 1 part of hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, 1 part of EDTA disodium, 1 part of methyl chloroisothiazolinone, 1 part of methyl isothiazolinone and purified water according to the required weight ratio by using weighing equipment for later use;
s2, preparation of auxiliary materials: sequentially adding sodium laureth sulfate, sodium lauroamphoacetate, sodium chloride, sodium methyl cocoyl taurate, disodium laureth sulfosuccinate, cocamide MEA, polyquaternary ammonium salt-22, PEG-40 hydrogenated castor oil, cocamidopropyl betaine, hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, disodium EDTA, methylchloroisothiazolinone, methylisothiazolinone and purified water which are weighed in the step S1 into a mixing and stirring device, then mixing at the rotating speed of 400r/min, gradually heating and stirring to 60 ℃, and stirring for 30min to obtain auxiliary materials;
s3, mixing of raw materials: adding 3% of salicylic acid in the main material composition measured in the step S1 into the auxiliary material prepared in the step S2, continuously stirring until the salicylic acid is completely dissolved, simultaneously cooling the mixing and stirring equipment, respectively adding 0.5% of piroctone olamine salt, 1% of sodium PCA, 0.5% of zinc PCA, 1% of white willow bark extract, 0.5% of camellia extract, 0.5% of safflower extract and 0.5% of rheum palmatum extract when the temperature is reduced to 50 ℃, stirring at the rotating speed of 600r/min until the materials are completely dissolved, thereby completing the mixing of the raw materials, wherein the camellia extract contains catechin, vitamin C, tannic acid and amino acid components, has excellent efficacy, contains soothing and antioxidant activities, contains carthamin extract, carthamin yellow and safflower oil components, and has obvious antioxidant, free radical scavenging and anti-inflammatory effects, the Rheum palmatum extract contains emodin and chrysophanol components, and can promote blood circulation of skin, improve skin permeability, promote absorption of effective components, inhibit bacteria, and astringe skin;
s4, adjusting the pH of the finished product: and (5) adding a pH regulator into the mixed raw materials obtained in the step S3, uniformly stirring and mixing, and regulating the pH value of the raw materials to 6.5 to obtain a finished shampoo product for daily maintenance of the skin with psoriasis.
Example 3
S1, selecting and weighing raw materials: firstly, respectively weighing 40 parts of main material composition, 5 parts of sodium laureth sulfate, 5 parts of sodium lauroamphoacetate, 5 parts of sodium chloride, 5 parts of sodium methyl cocoyl taurate, 5 parts of disodium laureth sulfosuccinate, 3 parts of cocamide MEA, 3 parts of polyquaternary ammonium salt-22, 3 parts of PEG-40 hydrogenated castor oil, 3 parts of cocamidopropyl betaine, 3 parts of hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, 3 parts of EDTA disodium, 3 parts of methylchloroisothiazolinone, 3 parts of methylisothiazolinone and purified water according to the required weight ratio by using weighing equipment for later use;
s2, preparation of auxiliary materials: sequentially adding sodium laureth sulfate, sodium lauroamphoacetate, sodium chloride, sodium methyl cocoyl taurate, disodium laureth sulfosuccinate, cocamide MEA, polyquaternary ammonium salt-22, PEG-40 hydrogenated castor oil, cocamidopropyl betaine, hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, disodium EDTA, methylchloroisothiazolinone, methylisothiazolinone and purified water which are weighed in the step S1 into a mixing and stirring device, then mixing at the rotating speed of 500r/min, gradually heating and stirring to 60 ℃, and stirring for 40min to obtain auxiliary materials;
s3, mixing of raw materials: adding 3% of salicylic acid in the main material composition measured in the step S1 into the auxiliary material prepared in the step S2, continuously stirring until the salicylic acid is completely dissolved, simultaneously cooling the mixing and stirring equipment, respectively adding 0.5% of piroctone olamine salt, 1% of sodium PCA, 0.5% of zinc PCA, 1% of white willow bark extract, 0.5% of camellia extract, 0.5% of safflower extract and 0.5% of rheum palmatum extract when the temperature is reduced to 50 ℃, stirring at the rotating speed of 700r/min until the materials are completely dissolved, thereby completing the mixing of the raw materials, wherein the camellia extract contains catechin, vitamin C, tannic acid and amino acid components, has excellent efficacy, contains soothing and antioxidant activities, contains carthamin extract, carthamin yellow and safflower oil components, and has obvious antioxidant, free radical scavenging and anti-inflammatory effects, the Rheum palmatum extract contains emodin and chrysophanol components, and can promote blood circulation of skin, improve skin permeability, promote absorption of effective components, inhibit bacteria, and astringe skin;
s4, adjusting the pH of the finished product: and (5) adding a pH regulator into the mixed raw materials obtained in the step S3, uniformly stirring and mixing, and regulating the pH value of the raw materials to 6.5 to obtain a finished shampoo product for daily maintenance of the skin with psoriasis.
Use case
The regular hospital conventional drug therapy for psoriasis is carried out on 100 patients with psoriasis vulgaris under the guidance of a hospital doctor, the conventional drug therapy is carried out by adopting the shampoo (50) and the common anti-dandruff and anti-itching shampoo (50) respectively during the hospital treatment period for one year, and the area change, the curative effect and the relapse aggravation condition of scalp skin lesions of the patients during the period of using the shampoo are compared with those of the common anti-dandruff and anti-itching shampoo. The size of the area reduction of scalp skin damage of patients during the shampoo using the invention and the ordinary dandruff-removing and itching-relieving shampoo are respectively calculated and counted, and the average value is calculated, and meanwhile, the statistical results of the curative effect and the recurrence exacerbation times are averaged. The statistical results are shown in tables 1, 2 and 3 below.
TABLE 1 comparison of average area reductions in skin lesions of two different shampoos
TABLE 2 comparison of the efficacy of two different shampoos
TABLE 3 relapse exacerbation of two different shampoo groups
As can be seen from Table 1, after the shampoo is used for one year, the average scalp skin damage area of 50 patients is more reduced than that of the common dandruff removal and itching relieving shampoo, the total effective rate of the shampoo is 98% and is obviously higher than the effective rate of 38% of the common dandruff removal and itching relieving shampoo after the shampoo is used from Table 2, and the relapse aggravation rate and the relapse aggravation frequency of the shampoo are obviously lower than those of the common dandruff removal and itching relieving shampoo after the shampoo is used from Table 3.
The plum female is 36 years old, and has intractable psoriasis on the head, dandruff is obviously reduced after the shampoo for daily maintenance of psoriasis skin prepared by the embodiment of the invention is used for 1-2 treatment courses, erythema on the affected part of the head is obviously reduced after the shampoo is continuously used for 3-5 treatment courses, the surface is not covered by dandruff, and the shampoo does not have itching feeling.
After the shampoo prepared by the embodiment of the invention is used for 1-2 courses of treatment, the diffusion of the head disease stops, and after the shampoo is continuously used for 3-5 courses of treatment, the red spot area of the diseased part on the head is obviously reduced, the red spot color becomes light, and the surface of the red spot area is not covered by skin fragments.
Mr. Su, 51 years old, the head suffers from psoriasis and scalp itch for a long time, so that bleeding and ulceration after scratching are caused, after the shampoo for daily maintenance of the psoriasis skin prepared by the embodiment of the invention is used for 1-2 treatment courses, the itch is reduced, after the shampoo is continuously used for 3-5 treatment courses, the scalp itch is relieved, and the red spot area at the affected part disappears.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. A shampoo formula for daily maintenance of psoriasis skin is characterized in that: the raw materials comprise the following components in parts by weight: 30-40 parts of a main material composition, 3-5 parts of sodium laureth sulfate, 3-5 parts of sodium lauroamphoacetate, 3-5 parts of sodium chloride, 3-5 parts of sodium methyl cocoyl taurate, 3-5 parts of disodium laureth sulfosuccinate, 1-3 parts of cocamide MEA, 221-3 parts of polyquaternary ammonium salt, 1-3 parts of PEG-40 hydrogenated castor oil, 1-3 parts of cocamidopropyl betaine, 1-3 parts of hydroxypropyl bis-hydroxyethyl dimethylammonium chloride, 1-3 parts of disodium EDTA, 1-3 parts of methyl chloroisothiazolinone, 1-3 parts of methyl isothiazolinone and the balance of purified water, wherein the main material composition is prepared from 3% of salicylic acid, 0.5% of piroctone ethanolamine salt, 1% of sodium, 0.5% of zinc PCA, 1% of white willow bark extract PCA, 1% of sodium PCA, and the balance of purified water respectively, 0.5 percent of camellia extract, 0.5 percent of safflower extract and 0.5 percent of rhubarb palmate extract.
2. The shampoo formulation for daily maintenance of psoriatic skin as claimed in claim 1, wherein: the raw materials comprise the following components: the main material composition comprises 35 parts of sodium laureth sulfate, 4 parts of sodium lauroamphoacetate, 4 parts of sodium chloride, 4 parts of sodium methyl cocoyl taurate, 4 parts of disodium laureth sulfosuccinate, 2 parts of cocamide MEA (membrane electrode assembly), 222 parts of polyquaternary ammonium salt, 2 parts of PEG-40 hydrogenated castor oil, 2 parts of cocamidopropyl betaine, 2 parts of hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, 2 parts of disodium EDTA (ethylene diamine tetraacetic acid), 2 parts of methylchloroisothiazolinone, 2 parts of methylisothiazolinone and the balance of purified water.
3. The shampoo formulation for daily maintenance of psoriatic skin as claimed in claim 1, wherein: the raw materials comprise the following components: the main material composition comprises 30 parts of sodium laureth sulfate, 3 parts of sodium lauroamphoacetate, 3 parts of sodium chloride, 3 parts of sodium methyl cocoyl taurate, 3 parts of disodium laureth sulfosuccinate, 1 part of cocamide MEA (membrane electrode assembly), 221 parts of polyquaternary ammonium salt-221, 1 part of PEG-40 hydrogenated castor oil, 1 part of cocamidopropyl betaine, 1 part of hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, 1 part of disodium EDTA (ethylene diamine tetraacetic acid), 1 part of methylchloroisothiazolinone, 1 part of methylisothiazolinone and the balance of purified water.
4. The shampoo formulation for daily maintenance of psoriatic skin as claimed in claim 1, wherein: the raw materials comprise the following components: the main material composition comprises 40 parts of sodium laureth sulfate, 5 parts of sodium lauroamphoacetate, 5 parts of sodium chloride, 5 parts of sodium methyl cocoyl taurate, 5 parts of disodium laureth sulfosuccinate, 3 parts of cocamide MEA (membrane electrode assembly), 223 parts of polyquaternary ammonium salt, 3 parts of PEG-40 hydrogenated castor oil, 3 parts of cocamidopropyl betaine, 3 parts of hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, 3 parts of disodium EDTA (ethylene diamine tetraacetic acid), 3 parts of methylchloroisothiazolinone, 3 parts of methylisothiazolinone and the balance of purified water.
5. The shampoo formulation for daily maintenance of psoriatic skin as claimed in claim 1, wherein: the camellia extract contains catechin, vitamin C, tannic acid and amino acid components.
6. The shampoo formulation for daily maintenance of psoriatic skin as claimed in claim 1, wherein: the safflower extract contains carthamin, safflower yellow and safflower oil.
7. The shampoo formulation for daily maintenance of psoriatic skin as claimed in claim 1, wherein: the Rheum palmatum extract contains emodin and chrysophanol components.
8. Shampoo formulation for the daily maintenance of psoriatic skin as claimed in any one of claims 1 to 4 wherein: the preparation method of the shampoo specifically comprises the following steps:
s1, selecting and weighing raw materials: firstly, respectively weighing a main material composition, sodium laureth sulfate, sodium lauroamphoacetate, sodium chloride, sodium methyl cocoyl taurate, disodium laureth sulfosuccinate, cocamide MEA (membrane electrode assembly), polyquaternary ammonium salt-22, PEG-40 hydrogenated castor oil, cocamidopropyl betaine, hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, disodium EDTA (ethylene diamine tetraacetic acid), methylchloroisothiazolinone, methylisothiazolinone and purified water in required parts by weight by using weighing equipment for later use;
s2, preparation of auxiliary materials: sequentially adding sodium laureth sulfate, sodium lauroamphoacetate, sodium chloride, sodium methyl cocoyl taurate, disodium laureth sulfosuccinate, cocamide MEA, polyquaternary ammonium salt-22, PEG-40 hydrogenated castor oil, cocamidopropyl betaine, hydroxypropyl bis-hydroxyethyl dimethyl ammonium chloride, disodium EDTA, methylchloroisothiazolinone, methylisothiazolinone and purified water which are weighed in the step S1 into a mixing and stirring device, then mixing at the rotation speed of 400-;
s3, mixing of raw materials: adding 3% of salicylic acid in the main material composition measured in the step S1 into the auxiliary material prepared in the step S2, continuously stirring until the salicylic acid is completely dissolved, simultaneously cooling the mixing and stirring equipment, respectively adding 0.5% of piroctone olamine salt, 1% of sodium PCA, 0.5% of zinc PCA, 1% of white willow bark extract, 0.5% of camellia extract, 0.5% of safflower extract and 0.5% of rheum palmatum extract when the temperature is reduced to 50 ℃, and stirring at the rotating speed of 600 + 700r/min until the materials are completely dissolved, thereby completing the mixing of the raw materials;
s4, adjusting the pH of the finished product: and (5) adding a pH regulator into the mixed raw materials obtained in the step S3, uniformly stirring and mixing, and regulating the pH value of the raw materials to 6.5 to obtain a finished shampoo product for daily maintenance of the skin with psoriasis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911065219.9A CN110652484A (en) | 2019-11-04 | 2019-11-04 | Shampoo formula for daily maintenance of psoriasis skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911065219.9A CN110652484A (en) | 2019-11-04 | 2019-11-04 | Shampoo formula for daily maintenance of psoriasis skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110652484A true CN110652484A (en) | 2020-01-07 |
Family
ID=69042761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911065219.9A Pending CN110652484A (en) | 2019-11-04 | 2019-11-04 | Shampoo formula for daily maintenance of psoriasis skin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110652484A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111568832A (en) * | 2020-06-28 | 2020-08-25 | 广东禾圣堂生物科技有限公司 | Traditional Chinese medicine scalp purification lotion and preparation method thereof |
| CN111973530A (en) * | 2020-09-08 | 2020-11-24 | 广州智尚生物科技有限公司 | Dandruff-removing and itching-relieving composition and application thereof |
| CN112206176A (en) * | 2020-10-14 | 2021-01-12 | 武汉赛锐希斯科技有限公司 | Bath cream for daily maintenance of psoriasis and seborrheic dermatitis skin |
| CN113925789A (en) * | 2021-09-15 | 2022-01-14 | 王御惟 | Novel scalp active shampoo powder and production process thereof |
| CN114727945A (en) * | 2019-11-21 | 2022-07-08 | 联合利华知识产权控股有限公司 | Cosmetic composition |
| CN115335029A (en) * | 2020-03-31 | 2022-11-11 | 联合利华知识产权控股有限公司 | Method of treating scalp |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105189531A (en) * | 2013-03-13 | 2015-12-23 | 新科蒂斯公司 | Peptides for skin rejuvenation and methods of using the same |
| CN107281048A (en) * | 2017-08-10 | 2017-10-24 | 佛山市润欣洗涤用品有限公司 | One kind is without silicone oil herbal treatment shampoo and preparation method thereof |
| CN107349122A (en) * | 2017-06-15 | 2017-11-17 | 曾万祥 | A kind of desquamation compositions and its application |
| CN109125213A (en) * | 2018-10-17 | 2019-01-04 | 深圳海悦生物科技有限公司 | It is a kind of to have Sage Extract, antibacterial anti-inflammatory and the clean hair-cream for repairing scalp effect |
| CN110123663A (en) * | 2019-05-16 | 2019-08-16 | 菏泽龙池生物科技有限公司 | A kind of shampoo and preparation method thereof cleaning scalp grease |
-
2019
- 2019-11-04 CN CN201911065219.9A patent/CN110652484A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105189531A (en) * | 2013-03-13 | 2015-12-23 | 新科蒂斯公司 | Peptides for skin rejuvenation and methods of using the same |
| US20160271109A1 (en) * | 2013-03-13 | 2016-09-22 | Neocutis Sa | Peptides For Skin Rejuvenation And Methods Of Using The Same |
| CN107349122A (en) * | 2017-06-15 | 2017-11-17 | 曾万祥 | A kind of desquamation compositions and its application |
| CN107281048A (en) * | 2017-08-10 | 2017-10-24 | 佛山市润欣洗涤用品有限公司 | One kind is without silicone oil herbal treatment shampoo and preparation method thereof |
| CN109125213A (en) * | 2018-10-17 | 2019-01-04 | 深圳海悦生物科技有限公司 | It is a kind of to have Sage Extract, antibacterial anti-inflammatory and the clean hair-cream for repairing scalp effect |
| CN110123663A (en) * | 2019-05-16 | 2019-08-16 | 菏泽龙池生物科技有限公司 | A kind of shampoo and preparation method thereof cleaning scalp grease |
Non-Patent Citations (4)
| Title |
|---|
| 张棨: "《云南山茶花产业发展导论》", 28 February 2011, 云南科技出版社 * |
| 武汉赛锐希斯科技有限公司: "选平去屑修护洗发水", 《国产普通化妆品备案信息》 * |
| 郭忻 等: "《美容中药学》", 31 July 2010, 上海科学技术出版社 * |
| 高学敏 等: "《中医美容学》", 31 January 2000, 中国科学技术出版社 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114727945A (en) * | 2019-11-21 | 2022-07-08 | 联合利华知识产权控股有限公司 | Cosmetic composition |
| CN114727945B (en) * | 2019-11-21 | 2024-07-26 | 联合利华知识产权控股有限公司 | Cosmetic composition |
| CN115335029A (en) * | 2020-03-31 | 2022-11-11 | 联合利华知识产权控股有限公司 | Method of treating scalp |
| CN111568832A (en) * | 2020-06-28 | 2020-08-25 | 广东禾圣堂生物科技有限公司 | Traditional Chinese medicine scalp purification lotion and preparation method thereof |
| CN111973530A (en) * | 2020-09-08 | 2020-11-24 | 广州智尚生物科技有限公司 | Dandruff-removing and itching-relieving composition and application thereof |
| CN112206176A (en) * | 2020-10-14 | 2021-01-12 | 武汉赛锐希斯科技有限公司 | Bath cream for daily maintenance of psoriasis and seborrheic dermatitis skin |
| CN113925789A (en) * | 2021-09-15 | 2022-01-14 | 王御惟 | Novel scalp active shampoo powder and production process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110652484A (en) | Shampoo formula for daily maintenance of psoriasis skin | |
| EA032439B1 (en) | Compositions and methods for treating surface wounds | |
| KR100673044B1 (en) | Topical Compositions for Transdermal Administration | |
| CN106309156A (en) | Ferulic acid acne fading solution and preparation method thereof | |
| CN103347507A (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
| JP2013060455A (en) | Composition using bee venom as active ingredient | |
| DE59409394D1 (en) | THERAPEUTIC SYSTEM FOR TREATING PSORIASIS | |
| CN106619823A (en) | Ointment for therapy of eczema and preparation method of same | |
| EP1791423B1 (en) | Compositions and methods for the management of hyperproliferative dermatological conditions | |
| WO2017129108A1 (en) | Silica gel for use in treating skin diseases | |
| US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
| US7442690B2 (en) | Topical treatment for psoriasis | |
| CN112206176A (en) | Bath cream for daily maintenance of psoriasis and seborrheic dermatitis skin | |
| CN110339298B (en) | A traditional Chinese medicine composition for externally used for treating chloasma, preparation method and preparation | |
| Zeharia et al. | Treatment with bifonazole shampoo for scalp seborrhea in infants and young children | |
| CN102872158A (en) | External drug combination for curing eczema and preparation method thereof | |
| CN110787077A (en) | Body lotion formula for daily maintenance of psoriasis skin | |
| Bharati et al. | A case study on the management of psoriasis (kitibha) by ayurvedic intervention | |
| RU2814362C1 (en) | Method of treating rosacea with solid persistent oedema by points | |
| CN114159376A (en) | A kind of liquiritigenin emulsified ointment and preparation method and application thereof | |
| Haisfield-Wolfe et al. | A nursing protocol for the management of perineal-rectal skin alterations. | |
| KR100438855B1 (en) | Oral anti-acnepreparation containing pine pollen extract | |
| CN102133324B (en) | Ointment for treating skin burn and scald | |
| Kowalzick et al. | An open pilot study of topical calcipotriol in seborrhoeic eczema | |
| KR102420354B1 (en) | Lotion composition having circulation and vitality and the manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200107 |